Skip to content
2000
Volume 5, Issue 2
  • ISSN: 2210-2965
  • E-ISSN:

Abstract

Genomic engineering has enormous potential along basic research, drug discovery and cell therapeutics. Many existing methods for targeted gene knockout mutagenesis or integration rely on homologous recombination. The low rate of spontaneous recombination in nearly all mammalian cell types, as well as the scale of screening, effort and time required to isolate the targeted events during genome modification, have hindered progress in this field. The present review has the objective to present latest improvements of technology to develop genetic modification to a clinical grade level so it can be used in human therapy.

Loading

Article metrics loading...

/content/journals/rpgm/10.2174/2210296506666160204231756
2015-08-01
2024-11-26
Loading full text...

Full text loading...

/content/journals/rpgm/10.2174/2210296506666160204231756
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test